MyoKardia Reports Second Quarter 2019 Financial Results
Announces Last Patient to be Enrolled in EXPLORER-HCM Phase 3 during the Week of
Topline Phase 2 Clinical Data from MAVERICK-HCM and MYK-491 on Track for Fourth Quarter 2019
Company to Host Conference Call and Webcast Today at
“We are now less than a year away from potentially game-changing pivotal data from our EXPLORER-HCM clinical trial of mavacamten in obstructive HCM, with activities in full swing for NDA preparation and potential commercial introduction of MyoKardia’s first product,” said Tassos Gianakakos, MyoKardia’s Chief Executive Officer. “The remainder of this year will see us share multiple meaningful clinical results including topline data from our Phase 2 MAVERICK-HCM study in patients with non-obstructive HCM and from our Phase 2 study of MYK-491 for patients with stable heart failure. We will also be advancing our third clinical-stage compound, MYK-224, into a Phase 1 clinical trial. Taken together, these events highlight the meaningful progress we continue to make in the development of much-needed new treatments for serious cardiovascular diseases.”
Recent Clinical Program Highlights
Mavacamten for Hypertrophic Cardiomyopathy (HCM)
- Enrollment in EXPLORER-HCM Phase 3 Clinical Study Nearing Completion: Patient enrollment for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating patients with symptomatic, obstructive HCM is scheduled to end next week. Clinical site engagement was high, allowing for enrollment above the target of 220 patients to be completed ahead of expectations.
MyoKardianow anticipates reporting topline data from the EXPLORER-HCM trial in the second quarter of 2020, ahead of the previous guidance of the second half of 2020.
- Completed Enrollment in the MAVERICK-HCM Phase 2 Clinical Trial: In May,
MyoKardiaannounced the completion of enrollment in the Phase 2 MAVERICK-HCM study of mavacamten for the treatment of non-obstructive HCM. The randomized, double-blind, placebo-controlled MAVERICK-HCM Phase 2 clinical trial is designed to assess the safety and tolerability of a 16-week treatment course of mavacamten in patients with non-obstructive HCM. MyoKardia plans to report topline data from the MAVERICK-HCM study in the fourth quarter of 2019.
- Published Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy: Results from an exploratory study demonstrated the potential to screen for obstructive HCM using a photoplethysmography (PPG) digital health device, similar to the optical sensors that monitor heart rate on commercially available fitness trackers. Continuous monitoring with a wrist-worn biosensor revealed differences in arterial pulse wave patterns between obstructive HCM patients and those of individuals without obstructive HCM. MyoKardia’s proprietary machine learning algorithm identified individuals with obstructive HCM with a sensitivity of 0.95 and a specificity of 0.98. The digital health substudy was conducted by
MyoKardiaas part of the company’s Phase 2 PIONEER-HCM trial of mavacamten.
MYK-491 for Dilated Cardiomyopathy (DCM)
- Presented results from Phase 1a Clinical Trial of MYK-491 at the
European Society of Cardiology Heart Failure Congress: First-in-human data from the Phase 1a clinical trial of MYK-491 in healthy volunteers showed the drug to be well tolerated. MYK-491 increased cardiac contractility by 5-20 percent across multiple echocardiographic parameters at higher drug concentrations, with minimal impact on diastolic function. MYK-491 is currently being studied in a Phase 2a multiple-ascending dose clinical trial for the treatment of patients with systolic heart failure, in which the heart is unable to contract sufficiently to meet the demands of the body. Data from this study are anticipated in the fourth quarter of 2019.
Recent Corporate Highlights
- Re-acquired U.S. Royalty Rights to HCM Programs from
Sanofi: MyoKardiacompleted the re-acquisition of U.S. royalty rights to mavacamten and MYK-224 from Sanofi. As consideration for the buyback of the U.S. royalty rights to these programs, MyoKardiapaid Sanofi $50 millionupfront, with an additional $30 millionpayable by June 30, 2020. Under the terms of the former license and collaboration agreement with Sanofi, Sanofiwas eligible for tiered royalties, ranging from 5 percent to 10 percent, on U.S. sales of mavacamten and MYK-224 in HCM or any additional indications.
Second Quarter 2019 Financial Results
- Cash Position: Cash, cash equivalents and investments (short-term and long-term) as of June 30, 2019 were $602.4 million, compared to
$394.8 millionas of December 31, 2018. The increase in the company’s cash position is primarily attributable to net proceeds of approximately $271.2 millionfrom MyoKardia’s follow-on offering of common stock, which priced in March 2019.
- Revenue: In the second quarter of 2019,
MyoKardiarecorded no revenue from collaborations, compared with $6.6 million during the same period in 2018. As of December 31, 2018, MyoKardiahad fulfilled all of its performance obligations to Sanofi, and no further revenue will be recorded from the Sanoficollaboration agreement.
- R&D Expenses: Research and development expenses were
$27.7 millionin the second quarter 2019, up from $17.2 million(net of Sanoficredits of $8.6and $4.3 million) for the same period in 2018. For the six months ended June 30, 2019, R&D expenses were $53.9 millioncompared to $33.8 millionin the first half of 2018, net of Sanoficredits of $18.5 millionand $7.1 million, respectively. The increase in R&D expenses was primarily driven by increases in clinical expenses related to the mavacamten and MYK-491 clinical trials, an increase in personnel-related costs and increases in contract research, chemistry and biology expenses related to discovery and pre-clinical programs.
- G&A Expenses: General and administrative expenses were $13.9 million for the three months ended
June 30, 2019, compared to $8.9 million for the same period in 2018. For the first half of 2019, G&A expenses totaled $27.4 millioncompared to $16.2 millionin the first half of 2018. The increase in G&A expense was primarily driven by an increase in personnel expenses and stock compensation due to higher headcount, as well as an increase in professional service and consulting fees.
- Net Loss: Net loss was
$38.2 million( $0.83loss per share) for the second quarter of 2019, compared to a net loss of $18.4 million( $0.49loss per share) for the second quarter of 2018. For the six months ended June 30, 2019, net loss was $75.6 million( $1.75loss per share) compared to $36.2 million( $0.99loss per share) during the same period of 2018.
Based on its current operating plans,
Conference Call and Webcast
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic potential of mavacamten and MYK-491, the Company’s ability to complete the enrollment of patients in its Phase 3 EXPLORER-HCM study of mavacamten in symptomatic oHCM, the availability of data from EXPLORER-HCM, as well as from the Phase 2 MAVERICK-HCM study in patients with non-obstructive HCM, and the MYK-491 Phase 2 study for patients with stable heart failure, the Company’s expectation with respect to release of data from these studies, the Company’s ability to advance MYK-224 into clinical development, and the timing of these events, as well as the Company’s projected cash runway, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements ad will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended
Senior Director, Corporate Communications and Investor Relations
Stern Investor Relations, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
|Cash and cash equivalents||$||443,693||$||246,122|
|Prepaid expenses and other current assets||4,316||4,760|
|Total current assets||562,801||319,446|
|Property and equipment, net||5,435||5,138|
|Operating lease right-of-use assets||1,756||—|
|Restricted cash and other||2,109||2,521|
|Liabilities and stockholders’ equity|
|Prepayment from collaboration partner||2,256||12,973|
|Operating lease liabilities - current||1,831||—|
|Total current liabilities||31,868||36,677|
|Other long-term liabilities||—||9|
|Commitments and contingencies|
|Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none
issued and outstanding
|Common stock, $0.0001 par value, 150,000,000 shares authorized
at June 30, 2019 and December 31, 2018; 46,098,059 and
40,288,949 shares issued and outstanding at June 30, 2019
and December 31, 2018, respectively
|Additional paid-in capital||861,880||573,183|
|Accumulated other comprehensive income (loss)||497||(67||)|
|Total stockholders’ equity||584,185||370,567|
|Total liabilities and stockholders’ equity||$||616,053||$||407,253|
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
|Three Months Ended
|Six Months Ended
|Collaboration and license revenue||$||—||$||6,639||$||—||$||11,970|
|Research and development||27,708||17,218||53,898||33,836|
|Selling, general and administrative||13,856||8,912||27,407||16,225|
|Total operating expenses||41,564||26,130||81,305||50,061|
|Loss from operations||(41,564||)||(19,491||)||(81,305||)||(38,091||)|
|Interest and other income, net||3,172||1,078||5,443||1,858|
|Loss before income taxes||(38,392||)||(18,413||)||(75,862||)||(36,233||)|
|Income tax benefit||(218||)||—||(218||)||—|
|Other comprehensive income (loss), net of tax effect of $219, $0, $219, $0, respectively||201||70||564||(67||)|
|Net loss per share, basic and diluted||$||(0.83||)||$||(0.49||)||$||(1.75||)||$||(0.99||)|
|Weighted average number of shares used to compute net loss
per share, basic and diluted
Source: MyoKardia, Inc.